India Preclinical Research Market Report: Forecast (2026-2032)

India Preclinical Research Market Key Takeaways

• The India Pre-Clinical Research Market was valued at USD 186 Million in 2025 and is projected to reach USD 213 Million by 2026 and USD 316 Million by 2032.
• The industry is projected to witness steady growth at a CAGR of 6.79% during 2026–2032.
• In Vivo Models lead the market by model type with an estimated 48.5% market share in 2026.
• Toxicology Studies dominate the market by service segment with an estimated 31.2% share in 2026.
• The market remains moderately fragmented, with the top five companies accounting for approximately 25% of total market share.

India Preclinical Research Market Size and Outlook

The India Pre-Clinical Research Market stood at USD 186 Million in 2025 and is projected to reach USD 316 Million by 2032 from USD 213 Million in 2026, growing at a CAGR of 6.79% during 2026–2032.

The India Preclinical Research Market is supported by increasing outsourcing of early-stage drug development activities, rising pipeline complexity, and growing reliance on preclinical services in India. Pharmaceutical and biotechnology companies are increasingly shifting toward external partners for preclinical studies, enabling faster timelines, improved cost efficiency, and access to specialized scientific capabilities. The market is also benefiting from the growing adoption of structured nonclinical research India workflows across discovery and IND-enabling stages.

According to the India BioEconomy Report, India hosts more than 8,500+ biotech startups as of 2024, making it one of the largest startup ecosystems globally. This expansion is creating a strong upstream innovation base that directly supports demand for preclinical research in India, particularly as healthcare and life sciences startups move from discovery to validation and regulatory submission stages. In addition, increasing venture capital inflows into biotech and health-tech segments are accelerating early-stage research activities requiring outsourced toxicology, pharmacology, and DMPK support.

Furthermore, the Indian Council of Medical Research supported research initiatives (2024), India continues to strengthen its translational research ecosystem through structured early-phase development programs and expanding clinical readiness infrastructure. This is reinforcing demand for preclinical drug development in India, especially for IND-enabling packages involving safety pharmacology, bioanalysis, and advanced model-based studies. The increasing integration of GLP-compliant systems and standardized biosafety protocols is further enhancing study quality and improving global acceptance of Indian CRO outputs.

Overall, the preclinical research market in India remains strongly positive, driven by rapid expansion of preclinical services in India, rising adoption of advanced platforms such as organoid and xenograft models, and continuous growth in startup-led innovation. The market is expected to evolve toward higher-value, integrated service models where CROs play a critical role in accelerating translational research and reducing drug development timelines.

India Preclinical Research Market Key Indicators

• According to the Department of Biotechnology (DBT) BioEconomy Report 2024, India’s bioeconomy reached approximately USD 151 billion in 2024, supported by rapid expansion in biotech research, life sciences startups, and R&D outsourcing activity. This growing innovation base is directly strengthening demand for preclinical services such as pharmacology, toxicology, and DMPK studies.
• As per the Indian Pharmaceutical Market (IPM) data reported for FY2024, the domestic pharma industry generated approximately USD 23.5 billion in revenue, with steady mid-to-high single-digit growth. This large-scale formulation and API-driven ecosystem continues to generate consistent demand for toxicology testing, bioanalysis, and DMPK studies.
• The Economic Survey 2024–25 reports that, the India’s total health expenditure in FY22 stood at approximately USD 0.109 trillion, equivalent to 3.8% of GDP, while government health expenditure accounted for 48.0% of total health expenditure. This reflects a strengthening healthcare base and increasing public funding support for research-led and translational healthcare activity.
• As per the Ministry of Health and Family Welfare, India’s pharmaceutical market for FY 2023–24 was valued at USD 50 billion, including domestic consumption of USD 23.5 billion. The size of the domestic pharma base directly supports outsourcing demand for preclinical toxicology, DMPK, pharmacology, and chemistry services.
• According to ICMR’s Phase I Clinical Trial Network, India has 4 dedicated Phase I institutions, and ICMR’s 2024 dengue vaccine program moved into a Phase III trial across 19 sites with more than 10,335 participants. This shows a strengthening clinical development pipeline and supports demand for India-enabling preclinical packages.

India Preclinical Research Market Scope

India Preclinical Research Market Growth Driver

Policy and Innovation-Led Drivers in the India Preclinical Research Market

India’s pre-clinical research ecosystem is witnessing strong momentum due to government-led biotechnology and biomanufacturing initiatives. According to PIB, the Bio-RIDE program (2024) has allocated nearly USD 180 million to support biofoundries and biomanufacturing hubs, strengthening early-stage innovation capacity. This is accelerating demand for preclinical studies in India as more discovery-stage programs progress toward structured validation and IND-enabling development supported by institutional frameworks and translational research programs.

In addition, Funding and industrial incentives are significantly boosting India's research infrastructure. Under the Department of Pharmaceuticals, the landmark Production Linked Incentive (PLI) scheme for medical devices provides an outlay of USD 410 million. This initiative is strategically designed to strengthen domestic manufacturing and foster innovation ecosystems. Improving access to advanced infrastructure directly drives higher demand for the country's preclinical research market and early-stage drug development support services.

Recent Trends

Integration of AI and Advanced Research Models Transforming Preclinical Research

The increasing adoption of advanced research technologies is emerging as a key trend in the India Pre-Clinical Research Market. Research organizations are increasingly integrating AI-driven drug discovery, computational chemistry, and in silico toxicology platforms to improve candidate selection, predict toxicity profiles, and accelerate early-stage development. These technologies are reducing dependency on conventional trial-and-error approaches while enabling faster and more data-driven preclinical research workflows. As pharmaceutical and biotechnology companies seek shorter development timelines, digital tools are becoming an integral part of modern preclinical programs.

At the same time, the industry is witnessing growing adoption of next-generation research models. According to the BioE3 Policy framework launched in 2024, India is actively promoting advanced biomanufacturing and biotechnology platforms, including innovations that support organoid research, synthetic biology, and translational science applications. This is encouraging wider use of patient-derived organoids (PDO models), 3D cell culture, and other advanced in vitro systems that offer improved human disease representation compared to traditional models. The shift toward these technologies is enhancing study accuracy, improving drug candidate screening efficiency, and strengthening the scientific capabilities of India's preclinical research ecosystem.

India Preclinical Research Market Opportunities and Challenges

Shortage of Advanced Disease Models Creating Opportunities for Next-Generation Research Platforms

The limited availability of advanced disease models remains a key challenge for the India Pre-Clinical Research Market. Despite growing demand for biologics, precision medicines, and complex therapeutic candidates, a large share of early-stage research continues to rely on conventional animal-based testing systems. According to industry studies, nearly 90% of drug candidates that demonstrate promising preclinical results fail during clinical development, highlighting the need for more predictive human-relevant models. The limited domestic availability of patient-derived organoids, transgenic models, and advanced microphysiological systems can increase study complexity and may require researchers to depend on imported technologies, resulting in higher costs and longer development timelines.

At the same time, this challenge is creating significant opportunities for next-generation research platforms. Government support through the Production Linked Incentive scheme for medical devices is strengthening domestic life-science infrastructure and innovation capabilities. In parallel, the regulatory environment is increasingly supportive of alternative testing approaches that improve translational accuracy. In 2024, Venus Remedies launched India's first dedicated organ-on-chip laboratory, introducing kidney-on-chip technology for drug toxicity evaluation. Such developments are expected to accelerate the adoption of organ-on-chip, 3D cell culture, and advanced disease-model platforms, creating new growth opportunities for high-value preclinical research and innovative drug development services across the country.

India Preclinical Research Market Segmentation

In Vivo Models Dominated the Market Due to Their Critical Role in Regulatory Safety and Efficacy Evaluation

In Vivo Models dominated the India Pre-Clinical Research industry, accounting for a 48.5% share in 2026. The segment continues to lead due to its critical role in evaluating systemic drug responses, safety profiles, toxicity, and pharmacokinetics before human testing. Regulatory authorities worldwide continue to require animal-based evidence for most Investigational New Drug (IND) submissions, making In Vivo Models an indispensable component of the drug development process. The segment particularly benefits from growing research activity in oncology, infectious diseases, vaccines, and biologics, where whole-organism response assessment remains essential.

The segment's dominance is further supported by India's established laboratory animal research ecosystem. According to the Committee for the Control and Supervision of Experiments on Animals (CCSEA), more than 3,000 institutions were registered for animal experimentation and breeding activities across India as of 2024. This extensive infrastructure supports large-scale toxicology, efficacy, and safety pharmacology studies conducted by pharmaceutical companies, biotechnology firms, and research institutions. Although advanced platforms such as patient-derived organoids and organ-on-chip systems are gaining traction, they currently complement rather than replace animal-based studies. By model type, the preclinical research industry is segmented into:

• In Vitro Models
• In Vivo Models
• Ex Vivo Models
• Patient-Derived Organoid (PDO) Models
• Patient-Derived Xenograft (PDX) Models

Toxicology Studies Lead the Industry Supported by Growing Demand for Regulatory Safety Evaluation

Toxicology Studies dominated the India Pre-Clinical Research Market, accounting for 31.2% share in 2026. The segment's leadership is primarily driven by the extensive safety assessment requirements associated with pharmaceuticals, biologics, vaccines, and biosimilars before they advance into human studies. Acute toxicity, repeat-dose toxicity, reproductive toxicity, and genotoxicity evaluations remain among the most widely outsourced services within the preclinical development process, making toxicology one of the largest revenue-generating service categories across the industry.

The segment also benefits from India's expanding laboratory infrastructure and internationally recognized quality standards. According to the National GLP Compliance Monitoring Authority (NGCMA), India had more than 50 GLP-certified test facilities as of 2024, providing strong capabilities for conducting globally accepted safety studies. In addition, the increasing development of biologics, cell therapies, and complex therapeutic candidates is generating higher demand for specialized toxicology programs, reinforcing the segment's leadership position within the preclinical drug development industry in India. Based on service type, the preclinical research industry is segmented into:

• Discovery & Chemistry Services
• Bioanalysis & DMPK Studies
• Bioanalytical Testing
• Toxicology Studies
• Safety Pharmacology
• Pharmacology & Efficacy Studies
• Other Preclinical Services

India Preclinical Research Market Competitive Analysis

The India Pre-Clinical Research Market is moderately fragmented, with the top five companies such as Syngene International Ltd., Jubilant Biosys Limited, Aragen Life Sciences Ltd., Eurofins Advinus Limited, and Veeda Clinical Research Limited accounting for 25% of the total industry share in 2026. These companies are actively investing in advanced disease models, bioanalytical capabilities, toxicology infrastructure, and digital drug discovery technologies to strengthen their service portfolios.

Leading Companies in the India Preclinical Research Market

• Syngene International Ltd.
• Jubilant Biosys Limited
• Aragen Life Sciences Ltd.
• Eurofins Advinus Limited
• Veeda Clinical Research Limited
• Bioneeds India Private Limited
• TCG Lifesciences Private Limited
• TheraIndx Lifesciences Pvt. Ltd.
• Accutest Research Laboratories Pvt. Ltd.
• JSS Medical Research Asia Pacific Private Limited

India Preclinical Research Industry News and Recent Developments

June 2024 Syngene International Launched Advanced Protein Production Platform

Syngene International launched a new protein production platform utilizing cell-line and transposon-based technology to accelerate biologics development. The platform supports monoclonal antibodies, biosimilars, bispecific antibodies, antibody-drug conjugates, and other recombinant proteins while improving development efficiency and reducing timelines.

Impact Analysis: The launch strengthens India's biologics research ecosystem and is expected to increase demand for advanced pharmacology, bioanalysis, and early-stage drug development services.